Skip to main content

Table 1 Exosomal biomarkers in diagnosis and prognosis of breast and ovarian cancers

From: Early diagnosis of breast and ovarian cancers by body fluids circulating tumor-derived exosomes

Exosomal marker Cancer type Clinical value References
let-7, miR-200 OC SKOV-3 and OVCAR-3 cell lines The exosomal let-7 miRNA expression was significantly greater in SKOV-3 (high invasive cell line) compared with OVCAR-3 (low invasive cell line)
The expression of miR-200 family was only identified in OVCAR-3 cell-derived exosomes
[84]
miR-21, miR-23b, miR-29a OC effusion supernatants High expression all three exosomal microRNAs was associated with poor survival [85]
miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214 OC patients serum Overexpression exosomal microRNAs in different stages of OC patients
Exosomal microRNAs were significantly lower in benign OC patients and negative in control cases
[52]
miR-373, miR-200a, miR-200b, miR-200c OC patients serum Overexpression all four exosomal microRNAs in OC patients
The levels of miR-200a, miR-200b, and miR-200c distinguished between malignant and benign OC
The increased levels of miR-200c and miR-200b were associated with CA125 values and shorter overall survival
[53]
miR-99a-5p OC patients serum MiR-99a-5p significantly elevated in OC patients compared to benign patients and healthy individuals [54]
miR-30a-5p OC patients urine High levels of miR-30a-5p in OC patients [58]
EpCAM, CD24 OC patients ascite High levels of EpCAM and CD24 in OC patients [50]
EpCAM, CD24, CA-125 OC patients plasma High levels of EpCAM, CD24, and CA-125 in OC patients [51]
EpCAM, CD24, CA-125, HER2, EGFR, FRα, CD9, CD63 OC patients plasma This panel distinguished early and late stage OC and discriminated patient groups from benign subjects [59]
CD24, L1CAM, ADAM10, EMMPRIN OC patients ascites Malignant ascites-derived exosomes contained tumor progression related proteins CD24, L1CAM, ADAM10, and, EMMPRIN. [57]
TGF-β1, MAGE3/6 OC patients plasma TGF-β1, MAGE3/6 distinguished OC patients from benign group and healthy controls [55]
Claudin-4 OC patients plasma High levels of Claudin-4 in OC patients [56]
CD24, EpCAM OC patients ascite EpCAM and CD24 were enriched in exosomes from ascites and pleural effusions [68]
BC patients pleural effusions and serum EpCAM was absent from BC patients serum
miR-373, miR-101 BC patients serum High levels of miR-373 and miR-101 in BC patients compared to benign patients and healthy individuals
Higher levels of miR-373 in more aggressive tumors (triple-negative and hormone receptor-negative BCs)
[63]
miR-105 BC patients serum Overexpression of miR-105 in BC cells was associated with high risk of metastasis [64]
miR-21, miR-1246 BC patients plasma High levels of miR-21, miR-1246 in BC samples compared to healthy subjects [65]
miR-223-3p BC patients plasma Higher levels of miR-223-3p in IDC group compared to DCIS patients and healthy controls [66]
miR-27a, miR-27b, miR-335, miR-365, miR-376c, miR-382, miR-422a, miR-433, miR-628 BC patients plasma miRNAs 27b, 335, 376c, 382, and 433 were upregulated in TNBC patients
miRNAs 27a, 27b, 365, and 628 were upregulated in HER2-positive BC patients
miR-422a was downregulated in HER2-positive BC patients
[74]
lncRNA HOTAIR BC patients plasma Positive correlation between the exosomal HOTAIR and HER2-positive BC patients [75]
CD82 BC patients plasma High levels of CD82 in BC exosomes is associated with high risk of metastasis [69]
Del-1 BC patients plasma Del-1 significantly elevated in BC patients compared to healthy controls [70]
GPC1 BC patients serum High levels of GPC1 in 75% of BC patients compared to healthy individuals [71]
Survivin-2B BC patients serum Survivin significantly elevated in BC patients compared to healthy controls [73]
GSTP1 BC patients serum GSTP1 significantly elevated in chemo-resistant BC patients compared to chemo-sensitivite BC group [77]
  1. OC Ovarian cancer, BC Breast cancer, IDC Invasive ductal carcinoma, DCIS Ductal carcinoma in situ, GPC1 glypican-1